Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit
PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John C. Jacobs and Chief Medical Officer, Dr. Jeffrey Dayno will present a company update and host investor meetings at the Oppenheimer Rare and Orphan Disease Summit on Friday, May 21, 2021.
A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences Investor Contact:
Harmony Biosciences Media Contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit-301293012.html
SOURCE Harmony Biosciences
Company Codes: NASDAQ-NMS:HRMY